Table 2. Hemodynamic parameters in the patients HCM and controls.
| Parameter | HCM participants (N=99) | Control participants (N=65) | P value |
|---|---|---|---|
| CP (W) | 1.19 (0.88–1.57) | 1.01 (0.87–1.29) | 0.03 |
| NCP (W/100 g) | 0.73 (0.57–0.90) | 1.12 (0.91–1.36) | <0.001 |
| EF (%) | 71.6 (63.3–74.9) | 61.5 (57.1–67.6) | <0.001 |
| SV (mL) | 88.7 (71.8–115.7) | 74.4 (63.0–90.4) | 0.002 |
| SV/BSA (mL/m2) | 50.1 (40.8–60.2) | 41.6 (35.6–49.4) | <0.001 |
| CO (L/min) | 6.01 (4.62–7.43) | 5.17 (4.41–6.19) | 0.01 |
| CO/BSA (L/m2/min) | 3.29 (2.68–3.98) | 2.90 (2.45–3.25) | 0.003 |
| EDV (mL) | 126.9 (105.8–160.5) | 125.6 (101.7–150.7) | 0.34 |
| EDV/BSA (mL/m2) | 72.5 (62.1–84.7) | 68.9 (58.1–78.3) | 0.11 |
| ESV (mL) | 40.7 (28.0–53.4) | 45.6 (37.2–57.4) | 0.01 |
| ESV/BSA (mL/m2) | 21.7 (16.0–28.4) | 25.6 (20.8–30.3) | 0.01 |
| LV mass (g) | 161.6 (126.2–210.5) | 97.0 (73.7–119.0) | <0.001 |
| Mass/BSA (g/m2) | 91.1 (75.8–108.7) | 52.6 (43.5–62.7) | <0.001 |
| LVMWT (mm) | 21.0 (16.0–28.4) | 9.8 (8.4–10.9) | <0.001 |
| LAV (mL) | 68.3 (50.9–88.0) | 45.2 (33.4–57.5) | <0.001 |
| LAV/BSA (mL/m2) | 40.5 (29.4–51.3) | 24.7 (18.0–31.1) | <0.001 |
| Obstruction | 61 [62] | – | – |
| Myocardial fibrosis | 85 [86] | – | – |
| LVMWT ≥30 mm | 10 [10] | – | – |
| NT-proBNP (pg/mL) | 196.3±37.6 | – | – |
| LGE (%) | 13.71±2.40 | – | – |
Normal distribution values are expressed as the mean ± standard error; abnormal distribution values are presented as the median (quartile 1 to quartile 3); categorical variables are displayed as the number [percentage]. HCM, hypertrophic cardiomyopathy; CP, cardiac power; NCP, normalized cardiac power; EF, ejection fraction; SV, stroke volume; BSA, body surface area; CO, cardiac output; EDV, end-diastole volume; ESV, end-systolic volume; LV, left ventricle; LVMWT, left ventricular maximal wall thickness; LAV, left atrium volume; NT-proBNP, N-terminal pro-B-type natriuretic peptide; LGE, late gadolinium enhanced.